Lupus
1 month 3 weeks ago
Which lupus nephritis patients are at higher risk for CKD? #Abstract0624 shows coexisting tubulointerstitial inflammation/damage (TII/TID) on renal biopsy is linked to CKD progression (HR 2.667, 95% CI: 1.333-5.335)
Risk high among Class III, IV, V and eGFR > 30
@RheumNow #ACR24
1 month 3 weeks ago
Mycophenolate isn't great for vaccine immunogenicity, but withholding MMF for one week after both doses of recombinant zoster vaccine boosts Ab titres ++ in this Brazilian RCT.
A week off post-vaccine: definitely worth considering in stable disease
#ACR24 ABST0247 @RheumNow https://t.co/lajS5DzRbD
1 month 3 weeks ago
CKD keeps a persistent low grade inflammatory state! Implications: CKD ⬆️risk for CV dz through different mech @RheumNow #ACR24 https://t.co/KcCvyTVaav
1 month 3 weeks ago
#ACR24 Ab#0771
ARID5B - transcription factor controls pathologic inflammatory fibroblast
ARID5B: RA risk locus on GWAS, also link to SLE, Graves
Binds to histone editors to epigenetically regulate fibroblast state
ARID5B deletion incr inflamm response, overexpr decr
@RheumNow https://t.co/ebKnX1uTuO
1 month 3 weeks ago
Role of X chromosome in autoimmune disease?
SLE increased in Klinefelter (XXY), decreased in Turner’s (XO)
X chromosome inactivation with Xist
Inductively transgenic expression of Xist in male mice induces autoantibodies
Year in Review #ACR24 Bridges
@RheumNow https://t.co/M88f0v0kpe
ACR24 Begins today. Many of the great presentations for this meeting come from industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and…
1 month 3 weeks ago
Study of 237 SLE pts shows mood disorders, fibromyalgia & chronic damage were major determinants of poorer Quality of life in SLE. mean SLEDAI-2k was 1.7, 29% had FM; 44% had chronic damage. https://t.co/JHzmleVMIK https://t.co/Sqk9K6oA7M
ACR 2024 starts tomorrow. Here are a few previews of abstracts to be presented, along with my recommendations of sessions you don’t want to miss.Previews:Abstract Number: 2527 Efficacy and…
Poster Hall